Mark White's most recent trade in Nexalin Technology Inc was a trade of 939,597 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nexalin Technology Inc | Mark White | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 939,597 | 1,387,024 | - | - | Stock Option (right to buy) | |
| Nexalin Technology Inc | Mark White | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 447,427 | 447,427 | - | - | Stock Option (right to buy) | |
| Rocket Pharmaceuticals Inc | Mark White | See Remarks | Sale of securities on an exchange or to another person at price $ 16.62 per share. | 31 Oct 2024 | 3,080 | 69,140 (0%) | 0% | 16.6 | 51,205 | Common Stock |
| Rocket Pharmaceuticals Inc | Mark White | See Remarks | Sale of securities on an exchange or to another person at price $ 20.39 per share. | 08 Jul 2024 | 3,026 | 72,220 (0%) | 0% | 20.4 | 61,715 | Common Stock |
| Rocket Pharmaceuticals Inc | Mark White | See Remarks | Sale of securities on an exchange or to another person at price $ 24.64 per share. | 08 Apr 2024 | 12,532 | 75,226 (0%) | 0% | 24.6 | 308,763 | Common Stock |
| Rocket Pharmaceuticals Inc | White Mark | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 32,727 | 32,727 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Mark White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 11,096 | 87,758 (0%) | 0% | 0 | Common Stock | |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 6.10 per share. | 20 Nov 2023 | 1,990 | 61,167 (0%) | 0% | 6.1 | 12,139 | Common Stock |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2023 | 26,200 | 26,200 | - | - | Stock Option (right to buy) | |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2023 | 2,146 | 2,146 | - | - | Stock Option (right to buy) | |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 12.61 per share. | 07 Apr 2023 | 3,000 | 59,177 (0%) | 0% | 12.6 | 37,830 | Common Stock |
| Rocket Pharmaceuticals Inc | Mark White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 76,662 | 76,662 (0%) | 0% | 0 | Common Stock, par value $0.01 | |
| Rocket Pharmaceuticals Inc | Mark White | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 57,739 | 57,739 | - | - | Stock Option (Right to Buy) | |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 5,967 | 5,967 | - | - | Stock Option (right to buy) | |
| Nexalin Technology Inc | Mark White | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Sep 2022 | 25,000 | 25,000 | - | - | Common stock warrants | |
| Nexalin Technology Inc | Mark White | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 4.15 per share. | 15 Sep 2022 | 25,000 | 309,127 | - | 4.2 | 103,750 | Common Stock |
| Nexalin Technology Inc | Mark White | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 4.15 per share. | 15 Sep 2022 | 25,000 | 289,627 | - | 4.2 | 103,750 | Common Stock |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Annovis Bio Inc | Mark White | Director | Purchase of securities on an exchange or from another person at price $ 27.40 per share. | 12 Oct 2021 | 5,000 | 56,177 (0%) | 0% | 27.4 | 137,000 | Common Stock |
| Annovis Bio Inc | Mark White | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2021 | 4,000 | 4,000 | - | - | Stock Option (right to buy) |